Xilio Therapeutics Inc (NASDAQ:XLO) has a beta value of -0.06 and has seen 2.02 million shares traded in the last trading session. The company, currently valued at $55.41M, closed the last trade at $1.07 per share which meant it gained $0.11 on the day or 11.01% during that session. The XLO stock price is -58.88% off its 52-week high price of $1.70 and 42.06% above the 52-week low of $0.62.
The consensus among analysts is that Xilio Therapeutics Inc (XLO) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Sporting 11.01% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the XLO stock price touched $1.07 or saw a rise of 6.96%. Year-to-date, Xilio Therapeutics Inc shares have moved 12.04%, while the 5-day performance has seen it change 19.29%. Over the past 30 days, the shares of Xilio Therapeutics Inc (NASDAQ:XLO) have changed 39.74%.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 84.71% from current levels. The projected low price target is $7.0 while the price target rests at a high of $7.0. In that case, then, we find that the current price level is -554.21% off the targeted high while a plunge would see the stock gain -554.21% from current levels.
Xilio Therapeutics Inc (XLO) estimates and forecasts
The company’s shares have gained 21.37% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -11.55% over the past 5 years. Earnings growth for 2025 is a modest 44.04% while over the next 5 years, the company’s earnings are expected to decrease by -4.67%.
XLO Dividends
Xilio Therapeutics Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
The top two institutional holders are BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with over 3.79 million shares worth more than $3.59 million. As of 2024-06-30, BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC held 13.5618% of shares outstanding.
The other major institutional holder is ROCK SPRINGS CAPITAL MANAGEMENT LP, with the holding of over 3.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.85 million and represent 10.7595% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 1.43% shares in the company for having 739.56 shares of worth $0.79 million while later fund manager owns 393.21 shares of worth $0.42 million as of Mar 31, 2025 , which makes it owner of about 0.76% of company’s outstanding stock.
